Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Ischemic Stroke-Pipeline Review, H1 2015

Ischemic Stroke-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Ischemic Stroke-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ischemic Stroke-Pipeline Review, H1 2015', provides an overview of the Ischemic Stroke's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Ischemic Stroke

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Ischemic Stroke and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Ischemic Stroke

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Ischemic Stroke pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Ischemic Stroke Overview 10

Therapeutics Development 11

Pipeline Products for Ischemic Stroke-Overview 11

Pipeline Products for Ischemic Stroke-Comparative Analysis 12

Ischemic Stroke-Therapeutics under Development by Companies 13

Ischemic Stroke-Therapeutics under Investigation by Universities/Institutes 19

Ischemic Stroke-Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Ischemic Stroke-Products under Development by Companies 24

Ischemic Stroke-Products under Investigation by Universities/Institutes 29

Ischemic Stroke-Companies Involved in Therapeutics Development 30

AB Science 30

Acorda Therapeutics, Inc. 31

Acticor Biotech 32

advanceCor GmbH 33

AGY Therapeutics, Inc. 34

Angion Biomedica Corp. 35

AstraZeneca PLC 36

Athersys, Inc. 37

Biogen Idec Inc. 38

BioTime, Inc. 39

Cetazam Therapeutics LLC 40

Concert Pharmaceuticals, Inc. 41

D-Pharm Ltd. 42

Daiichi Sankyo Company, Limited 43

DiaMedica Inc. 44

Digna Biotech, S.L. 45

Genervon Biopharmaceuticals, LLC 46

GlaxoSmithKline plc 47

Glucox Biotech AB 48

Grifols, S.A. 49

Huons Co., Ltd. 50

International Stem Cell Corporation 51

Laboratoires Pierre Fabre SA 52

Lumosa Therapeutics Co., Ltd. 53

MediaPharma s.r.l. 54

Mesoblast Limited 55

Mitsubishi Tanabe Pharma Corporation 56

Neuralstem, Inc. 57

Neurotec Pharma SL 58

NeuroVive Pharmaceutical AB 59

Panacea Pharmaceuticals, Inc. 60

Pharmicell Co., Ltd. 61

PhytoHealth Corporation 62

Pluristem Therapeutics Inc. 63

Regado Biosciences, Inc. 64

Remedy Pharmaceuticals, Inc. 65

ReNeuron Group plc 66

SanBio, Inc. 67

Saneron CCEL Therapeutics, Inc. 68

Simcere Pharmaceutical Group 69

Stemedica Cell Technologies, Inc. 70

Stempeutics Research Private Limited 71

SynZyme Technologies, LLC 72

Tenax Therapeutics, Inc. 73

Vicore Pharma AB 74

Virogenomics, Inc. 75

Ischemic Stroke-Therapeutics Assessment 76

Assessment by Monotherapy Products 76

Assessment by Target 77

Assessment by Mechanism of Action 80

Assessment by Route of Administration 83

Assessment by Molecule Type 85

Drug Profiles 87

3K3A-APC-Drug Profile 87

AB-144-Drug Profile 89

ACT-017-Drug Profile 90

Aptamers for Cardiovascular Diseases-Drug Profile 91

BB-3-Drug Profile 92

BSc-2118-Drug Profile 94

C-10068-Drug Profile 95

C-21-Drug Profile 96

Cerecellgram-Stroke-Drug Profile 98

CET-101-Drug Profile 99

CNB-001-Drug Profile 100

dalfampridine ER-Drug Profile 102

DB-017-Drug Profile 104

DM-199-Drug Profile 105

Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction-Drug Profile 106

DS-1040-Drug Profile 107

glyburide-Drug Profile 108

GM-602-Drug Profile 110

GSK-249320-Drug Profile 111

GXNPC-1-Drug Profile 113

HBN-1-Drug Profile 114

HU-010-Drug Profile 115

Human Plasmin-Drug Profile 116

Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases-Drug Profile 118

levomilnacipran hydrochloride ER-Drug Profile 121

LT-3001-Drug Profile 123

Lysimab-Drug Profile 124

masitinib-Drug Profile 125

Memantine Nitrone-Drug Profile 128

Mesenchymal Stem Cells-Drug Profile 129

Monoclonal Antibody for Cardiovascular and Ischemic Stroke-Drug Profile 131

MP-124-Drug Profile 132

MPHE-001A-Drug Profile 133

MultiStem-Drug Profile 134

natalizumab-Drug Profile 137

NSI-566-Drug Profile 139

NTKC-005-Drug Profile 141

NVP-014-Drug Profile 142

NVX-208-Drug Profile 143

Oxycyte-Drug Profile 144

PAN-811-Drug Profile 146

Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke-Drug Profile 148

PHN-014-Drug Profile 149

phycocyanobilin-Drug Profile 150

Pinocembrin-Drug Profile 151

Polyglactin 370 for Ischemic Stroke-Drug Profile 152

PR-15-Drug Profile 153

prasugrel hydrochloride-Drug Profile 155

Protein for Ischemic Stroke-Drug Profile 158

Protein for Ischemic Stroke-Drug Profile 159

Protein for Ischemic Stroke-Drug Profile 160

Recombinant Peptide for Ischemic Cerebral Stroke-Drug Profile 161

Recombinant Plasmin-Drug Profile 163

Recombinant Protein for Ischemic Cerebral Stroke-Drug Profile 164

Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis-Drug Profile 165

ReN-001-Drug Profile 166

RTL-551-Drug Profile 167

SB-623-Drug Profile 168

SIM-071201-Drug Profile 169

Small Molecule to Activate Epsilon PKC for Ischemic Stroke-Drug Profile 170

Small Molecule to Block Sodium Channels for Ischemic Stroke-Drug Profile 171

Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke-Drug Profile 172

Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke-Drug Profile 173

Small Molecules for Brain Ischemia and Ischemic Stroke-Drug Profile 174

Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure-Drug Profile 175

Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke-Drug Profile 176

Small Molecules to Inhibit AGY-207 for Ischemic Stroke-Drug Profile 177

Small Molecules to Inhibit AGY-221 for Ischemic Stroke-Drug Profile 178

Small Molecules to Inhibit CaMKII for Ischemic Stroke-Drug Profile 179

Small Molecules to Inhibit Cysteine Protease for Ischemic Stroke-Drug Profile 180

Small Molecules to Inhibit Kinase for Ischemic Stroke-Drug Profile 181

Small Molecules to Inhibit Protein Kinase for Ischemic Stroke-Drug Profile 182

SMTP-7-Drug Profile 183

Stem Cell Therapy for Ischemic Stroke-Drug Profile 184

Stem Cell Therapy for Liver Insufficiency, Acute Ischemic Stroke and Tibial Fractures-Drug Profile 185

Stem Cell Therapy for Parkinson Disease and Ishemia Stroke-Drug Profile 186

Stem Cell Therapy for Parkinson's Disease, Traumatic Brain Injury and Stroke-Drug Profile 187

Stempeucel-Drug Profile 189

StromAb-Drug Profile 192

T-33-Drug Profile 193

THR-18-Drug Profile 194

ticagrelor-Drug Profile 195

TPAi-14-Drug Profile 199

TPAi-23-Drug Profile 200

TXA-127-Drug Profile 201

TXA-302-Drug Profile 203

VACNO-Drug Profile 205

Ischemic Stroke-Recent Pipeline Updates 206

Ischemic Stroke-Dormant Projects 260

Ischemic Stroke-Discontinued Products 264

Ischemic Stroke-Product Development Milestones 267

Featured News & Press Releases 267

Appendix 274

Methodology 274

Coverage 274

Secondary Research 274

Primary Research 274

Expert Panel Validation 274

Contact Us 274

Disclaimer 275

List of Tables

Number of Products under Development for Ischemic Stroke, H1 2015 17

Number of Products under Development for Ischemic Stroke-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Development by Companies, H1 2015 (Contd..4) 24

Number of Products under Investigation by Universities/Institutes, H1 2015 26

Comparative Analysis by Late Stage Development, H1 2015 27

Comparative Analysis by Clinical Stage Development, H1 2015 28

Comparative Analysis by Early Stage Development, H1 2015 29

Products under Development by Companies, H1 2015 30

Products under Development by Companies, H1 2015 (Contd..1) 31

Products under Development by Companies, H1 2015 (Contd..2) 32

Products under Development by Companies, H1 2015 (Contd..3) 33

Products under Development by Companies, H1 2015 (Contd..4) 34

Products under Investigation by Universities/Institutes, H1 2015 35

Ischemic Stroke-Pipeline by AB Science, H1 2015 36

Ischemic Stroke-Pipeline by Acorda Therapeutics, Inc., H1 2015 37

Ischemic Stroke-Pipeline by Acticor Biotech, H1 2015 38

Ischemic Stroke-Pipeline by advanceCor GmbH, H1 2015 39

Ischemic Stroke-Pipeline by AGY Therapeutics, Inc., H1 2015 40

Ischemic Stroke-Pipeline by Angion Biomedica Corp., H1 2015 41

Ischemic Stroke-Pipeline by AstraZeneca PLC, H1 2015 42

Ischemic Stroke-Pipeline by Athersys, Inc., H1 2015 43

Ischemic Stroke-Pipeline by Biogen Idec Inc., H1 2015 44

Ischemic Stroke-Pipeline by BioTime, Inc., H1 2015 45

Ischemic Stroke-Pipeline by Cetazam Therapeutics LLC, H1 2015 46

Ischemic Stroke-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 47

Ischemic Stroke-Pipeline by D-Pharm Ltd., H1 2015 48

Ischemic Stroke-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 49

Ischemic Stroke-Pipeline by DiaMedica Inc., H1 2015 50

Ischemic Stroke-Pipeline by Digna Biotech, S.L., H1 2015 51

Ischemic Stroke-Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015 52

Ischemic Stroke-Pipeline by GlaxoSmithKline plc, H1 2015 53

Ischemic Stroke-Pipeline by Glucox Biotech AB, H1 2015 54

Ischemic Stroke-Pipeline by Grifols, S.A., H1 2015 55

Ischemic Stroke-Pipeline by Huons Co., Ltd., H1 2015 56

Ischemic Stroke-Pipeline by International Stem Cell Corporation, H1 2015 57

Ischemic Stroke-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 58

Ischemic Stroke-Pipeline by Lumosa Therapeutics Co., Ltd., H1 2015 59

Ischemic Stroke-Pipeline by MediaPharma s.r.l., H1 2015 60

Ischemic Stroke-Pipeline by Mesoblast Limited, H1 2015 61

Ischemic Stroke-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 62

Ischemic Stroke-Pipeline by Neuralstem, Inc., H1 2015 63

Ischemic Stroke-Pipeline by Neurotec Pharma SL, H1 2015 64

Ischemic Stroke-Pipeline by NeuroVive Pharmaceutical AB, H1 2015 65

Ischemic Stroke-Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 66

Ischemic Stroke-Pipeline by Pharmicell Co., Ltd., H1 2015 67

Ischemic Stroke-Pipeline by PhytoHealth Corporation, H1 2015 68

Ischemic Stroke-Pipeline by Pluristem Therapeutics Inc., H1 2015 69

Ischemic Stroke-Pipeline by Regado Biosciences, Inc., H1 2015 70

Ischemic Stroke-Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 71

Ischemic Stroke-Pipeline by ReNeuron Group plc, H1 2015 72

Ischemic Stroke-Pipeline by SanBio, Inc., H1 2015 73

Ischemic Stroke-Pipeline by Saneron CCEL Therapeutics, Inc., H1 2015 74

Ischemic Stroke-Pipeline by Simcere Pharmaceutical Group, H1 2015 75

Ischemic Stroke-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 76

Ischemic Stroke-Pipeline by Stempeutics Research Private Limited, H1 2015 77

Ischemic Stroke-Pipeline by SynZyme Technologies, LLC, H1 2015 78

Ischemic Stroke-Pipeline by Tenax Therapeutics, Inc., H1 2015 79

Ischemic Stroke-Pipeline by Vicore Pharma AB, H1 2015 80

Ischemic Stroke-Pipeline by Virogenomics, Inc., H1 2015 81

Assessment by Monotherapy Products, H1 2015 82

Number of Products by Stage and Target, H1 2015 84

Number of Products by Stage and Mechanism of Action, H1 2015 87

Number of Products by Stage and Route of Administration, H1 2015 90

Number of Products by Stage and Molecule Type, H1 2015 92

Ischemic Stroke Therapeutics-Recent Pipeline Updates, H1 2015 212

Ischemic Stroke-Dormant Projects, H1 2015 266

Ischemic Stroke-Dormant Projects (Contd..1), H1 2015 267

Ischemic Stroke-Dormant Projects (Contd..2), H1 2015 268

Ischemic Stroke-Dormant Projects (Contd..3), H1 2015 269

Ischemic Stroke-Discontinued Products, H1 2015 270

Ischemic Stroke-Discontinued Products (Contd..1), H1 2015 271

Ischemic Stroke-Discontinued Products (Contd..2), H1 2015 272

List of Figures

Number of Products under Development for Ischemic Stroke, H1 2015 17

Number of Products under Development for Ischemic Stroke-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 28

Comparative Analysis by Early Stage Products, H1 2015 29

Assessment by Monotherapy Products, H1 2015 82

Number of Products by Top 10 Targets, H1 2015 83

Number of Products by Stage and Top 10 Targets, H1 2015 83

Number of Products by Top 10 Mechanism of Actions, H1 2015 86

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 86

Number of Products by Top 10 Routes of Administration, H1 2015 89

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 90

Number of Products by Top 10 Molecule Types, H1 2015 91

Number of Products by Stage and Top 10 Molecule Types, H1 2015 92

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

Acorda Therapeutics, Inc.

Acticor Biotech

advanceCor GmbH

AGY Therapeutics, Inc.

Angion Biomedica Corp.

AstraZeneca PLC

Athersys, Inc.

Biogen Idec Inc.

BioTime, Inc.

Cetazam Therapeutics LLC

Concert Pharmaceuticals, Inc.

D-Pharm Ltd.

Daiichi Sankyo Company, Limited

DiaMedica Inc.

Digna Biotech, S.L.

Genervon Biopharmaceuticals, LLC

GlaxoSmithKline plc

Glucox Biotech AB

Grifols, S.A.

Huons Co., Ltd.

International Stem Cell Corporation

Laboratoires Pierre Fabre SA

Lumosa Therapeutics Co., Ltd.

MediaPharma s.r.l.

Mesoblast Limited

Mitsubishi Tanabe Pharma Corporation

Neuralstem, Inc.

Neurotec Pharma SL

NeuroVive Pharmaceutical AB

Panacea Pharmaceuticals, Inc.

Pharmicell Co., Ltd.

PhytoHealth Corporation

Pluristem Therapeutics Inc.

Regado Biosciences, Inc.

Remedy Pharmaceuticals, Inc.

ReNeuron Group plc

SanBio, Inc.

Saneron CCEL Therapeutics, Inc.

Simcere Pharmaceutical Group

Stemedica Cell Technologies, Inc.

Stempeutics Research Private Limited

SynZyme Technologies, LLC

Tenax Therapeutics, Inc.

Vicore Pharma AB

Virogenomics, Inc.

Ischemic Stroke Therapeutic Products under Development, Key Players in Ischemic Stroke Therapeutics, Ischemic Stroke Pipeline Overview, Ischemic Stroke Pipeline, Ischemic Stroke Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com